Alvotech SA

Alvotech S.A. is a global biopharmaceutical company specializing in the development, manufacturing, and delivery of high-quality biosimilar medicines. Biosimilars are biologic products highly similar to approved reference medicines, designed to expand patient access to affordable treatments for conditions in areas such as oncology, immunology, and autoimmune diseases. The company employs a vertically integrated approach, managing processes from cell line development through fill-and-finish manufacturing, which enables control over quality, scale, and efficiency. Alvotech maintains a robust pipeline of biosimilar candidates targeting major therapeutic needs and relies on strategic partnerships with pharmaceutical companies for global commercialization. This model supports its mission to make proven biologic therapies accessible to patients worldwide. Founded in 2013 and headquartered in Reykjavik, Iceland, Alvotech focuses on producing cost-competitive alternatives that meet rigorous standards while enhancing healthcare outcomes through expanded availability of essential medicines.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Robert Wessman

Employees

1,012

Headquarters

Luxembourg, Luxembourg

Website

www.alvotech.com